Purpose Combination therapy with docetaxel and trabectedin was examined in individuals with advanced malignancies. received a median of four cycles of treatment. MTD was 1.3 mg/m2 trabectedin and 60 mg/m2 docetaxel for individuals with limited and 1.1 mg/m2 trabectedin and 60 mg/m2 docetaxel for individuals with unlimited previous chemotherapy. Dose-limiting toxicities (during routine 1) included… Continue reading Purpose Combination therapy with docetaxel and trabectedin was examined in individuals